Compare · AXGT vs TRIL
AXGT vs TRIL
Side-by-side comparison of Axovant Gene Therapies Ltd. (AXGT) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGT and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TRIL carries a market cap of $1.94B.
- TRIL has more recent analyst coverage (5 ratings vs 0 for AXGT).
- Company
- Axovant Gene Therapies Ltd.
- Trillium Therapeutics Inc.
- Price
- -
- $19.30-3.45%
- Market cap
- -
- $1.94B
- 1M return
- -
- -3.79%
- 1Y return
- -
- -5.02%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 5
Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Latest AXGT
- Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
- Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
- Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020
- Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years
- Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020
- Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
- Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer
- Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy
- Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th
Latest TRIL
- Defiance ETFs Announces Closure of Select Funds
- Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
- Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
- 10 Psychedelics CEOs To Pay Attention To In 2022
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
- SEC Form 15-12B filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
- SEC Form 4 filed by Pucci Paolo